Redwood Investments Boosted Puma Biotechnology (PBYI) Stake; Hca Healthcare (HCA) Shareholder Chieftain Capital Management Cut Its Position by $53.15 Million as Stock Value Rose

HCA Healthcare, Inc. (NYSE:HCA) Logo

John Shapiro decreased its stake in Hca Healthcare Inc (HCA) by 22.21% based on its latest 2018Q1 regulatory filing with the SEC. Chieftain Capital Management Inc sold 547,986 shares as the company’s stock rose 3.67% while stock markets declined. The hedge fund run by John Shapiro held 1.92M shares of the health care company at the end of 2018Q1, valued at $186.12 million, down from 2.47 million at the end of the previous reported quarter. Chieftain Capital Management Inc who had been investing in Hca Healthcare Inc for a number of months, seems to be less bullish one the $36.08 billion market cap company. The stock decreased 0.40% or $0.41 during the last trading session, reaching $103.28. About 1.07 million shares traded. HCA Healthcare, Inc. (NYSE:HCA) has risen 24.76% since May 30, 2017 and is uptrending. It has outperformed by 12.19% the S&P500.

Redwood Investments Llc increased its stake in Puma Biotechnology Inc (PBYI) by 8.45% based on its latest 2018Q1 regulatory filing with the SEC. Redwood Investments Llc bought 15,178 shares as the company’s stock declined 23.56% with the market. The institutional investor held 194,773 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $13.25 million, up from 179,595 at the end of the previous reported quarter. Redwood Investments Llc who had been investing in Puma Biotechnology Inc for a number of months, seems to be bullish on the $1.95 billion market cap company. The stock decreased 0.58% or $0.3 during the last trading session, reaching $51.6. About 257,133 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has declined 33.50% since May 30, 2017 and is downtrending. It has underperformed by 46.07% the S&P500.

Investors sentiment increased to 0.96 in 2018 Q1. Its up 0.18, from 0.78 in 2017Q4. It is positive, as 38 investors sold HCA shares while 194 reduced holdings. 94 funds opened positions while 129 raised stakes. 243.77 million shares or 2.87% less from 250.97 million shares in 2017Q4 were reported. Macquarie Gru, a Australia-based fund reported 10,731 shares. Oppenheimer Asset Inc stated it has 0.01% of its portfolio in HCA Healthcare, Inc. (NYSE:HCA). Brown Advisory Incorporated invested in 2,875 shares or 0% of the stock. Greenleaf reported 0.01% in HCA Healthcare, Inc. (NYSE:HCA). Piedmont Advsr Ltd Company reported 42,448 shares. Raymond James Fincl reported 0.03% stake. Ipg Investment Advsrs Limited Liability Corporation has 5,000 shares for 0% of their portfolio. Toronto Dominion Bancshares holds 153,501 shares or 0.03% of its portfolio. Lsv Asset invested in 0.77% or 5.00M shares. Millennium Mngmt Ltd Com reported 0.17% in HCA Healthcare, Inc. (NYSE:HCA). 3,367 were reported by Da Davidson And. Parallax Volatility Advisers Limited Partnership stated it has 8,064 shares or 0% of all its holdings. Sg Americas Llc has invested 0.02% in HCA Healthcare, Inc. (NYSE:HCA). Panagora Asset Management stated it has 22,985 shares. Alps Advsr Inc accumulated 5,550 shares.

Analysts await HCA Healthcare, Inc. (NYSE:HCA) to report earnings on July, 24. They expect $2.15 earnings per share, up 22.86% or $0.40 from last year’s $1.75 per share. HCA’s profit will be $751.00 million for 12.01 P/E if the $2.15 EPS becomes a reality. After $2.33 actual earnings per share reported by HCA Healthcare, Inc. for the previous quarter, Wall Street now forecasts -7.73% negative EPS growth.

Among 30 analysts covering HCA Holdings (NYSE:HCA), 20 have Buy rating, 2 Sell and 8 Hold. Therefore 67% are positive. HCA Holdings had 102 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Sunday, August 27 with “Buy”. The stock of HCA Healthcare, Inc. (NYSE:HCA) has “Buy” rating given on Wednesday, April 25 by Cantor Fitzgerald. The company was maintained on Monday, July 17 by RBC Capital Markets. The rating was maintained by Piper Jaffray on Tuesday, January 30 with “Hold”. Mizuho downgraded HCA Healthcare, Inc. (NYSE:HCA) on Wednesday, November 9 to “Neutral” rating. The stock has “Buy” rating by Mizuho on Friday, August 14. Mizuho maintained HCA Healthcare, Inc. (NYSE:HCA) on Thursday, October 15 with “Buy” rating. The firm has “Overweight” rating given on Thursday, November 30 by JP Morgan. The firm earned “Outperform” rating on Wednesday, February 1 by RBC Capital Markets. The rating was maintained by RBC Capital Markets on Wednesday, October 28 with “Outperform”.

More notable recent HCA Healthcare, Inc. (NYSE:HCA) news were published by: Fool.com which released: “HCA Healthcare’s Profits Jump” on May 02, 2018, also Seekingalpha.com with their article: “Reuters: HCA, KKR teaming on Envision buyout bid; EVHC +7.8%” published on May 18, 2018, Seekingalpha.com published: “Tracking Larry Robbins’ Glenview Capital Management Portfolio – Q1 2018 Update” on May 25, 2018. More interesting news about HCA Healthcare, Inc. (NYSE:HCA) were released by: Bizjournals.com and their article: “TriStar announces more than $500 million in Middle Tennessee investments” published on May 14, 2018 as well as Bizjournals.com‘s news article titled: “Report: HCA makes offer to buy Envision” with publication date: May 21, 2018.

Since December 15, 2017, it had 2 insider buys, and 20 sales for $57.09 million activity. $1.51 million worth of stock was sold by YUSPEH ALAN R on Wednesday, January 31. On Friday, December 15 Cuffe Michael S. sold $207,912 worth of HCA Healthcare, Inc. (NYSE:HCA) or 2,400 shares. Englebright Jane D. had sold 5,822 shares worth $596,580. Shares for $3.93 million were sold by Perlin Jonathan B on Friday, February 16. The insider Sowell Joseph A III sold 22,025 shares worth $2.24M. Reiner Deborah M also sold $870,619 worth of HCA Healthcare, Inc. (NYSE:HCA) shares.

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Puma Biotechnology Inc had 63 analyst reports since August 27, 2015 according to SRatingsIntel. The company was initiated on Thursday, September 3 by Citigroup. On Wednesday, September 27 the stock rating was maintained by Credit Suisse with “Buy”. The rating was initiated by Barclays Capital with “Buy” on Wednesday, September 6. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, July 6. The rating was maintained by Cowen & Co with “Buy” on Monday, June 5. The rating was maintained by Citigroup on Thursday, May 10 with “Buy”. RBC Capital Markets maintained the shares of PBYI in report on Thursday, May 25 with “Sector Perform” rating. JP Morgan initiated Puma Biotechnology, Inc. (NASDAQ:PBYI) rating on Thursday, August 27. JP Morgan has “Overweight” rating and $122 target. J.P. Morgan maintained Puma Biotechnology, Inc. (NASDAQ:PBYI) rating on Monday, June 5. J.P. Morgan has “Buy” rating and $8900 target. Stifel Nicolaus upgraded the stock to “Buy” rating in Wednesday, September 21 report.

More news for Puma Biotechnology, Inc. (NASDAQ:PBYI) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018. Nasdaq.com‘s article titled: “Here’s Why Puma Biotechnology Inc. Is Sinking Today” and published on May 10, 2018 is yet another important article.

Redwood Investments Llc, which manages about $756.78M and $1.36 billion US Long portfolio, decreased its stake in Svb Finl Group (NASDAQ:SIVB) by 11,684 shares to 50,482 shares, valued at $12.12M in 2018Q1, according to the filing. It also reduced its holding in Thor Inds Inc (NYSE:THO) by 19,188 shares in the quarter, leaving it with 63,475 shares, and cut its stake in Abiomed Inc (NASDAQ:ABMD).

Investors sentiment decreased to 1.14 in 2018 Q1. Its down 0.51, from 1.65 in 2017Q4. It turned negative, as 35 investors sold PBYI shares while 44 reduced holdings. 21 funds opened positions while 69 raised stakes. 34.13 million shares or 1.66% less from 34.70 million shares in 2017Q4 were reported. Virginia Retirement Et Al holds 0.02% in Puma Biotechnology, Inc. (NASDAQ:PBYI) or 21,100 shares. Vanguard Group reported 0.01% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Alliancebernstein LP accumulated 0% or 67,900 shares. Aqr Cap Ltd Limited Liability Company holds 0% or 43,872 shares. 286,906 are owned by Bancorp Of America De. Barclays Pcl holds 14,091 shares. Orbimed stated it has 2.23% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Bnp Paribas Arbitrage Sa owns 0% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 99,995 shares. Metropolitan Life Ins Ny holds 9,324 shares. 11,232 were reported by Clarivest Asset Limited Liability Corp. Sivik Glob Health Ltd Limited Liability Company reported 25,000 shares. Amer Gp Incorporated Inc has 18,644 shares for 0% of their portfolio. Teacher Retirement System Of Texas accumulated 0% or 6,646 shares. Franklin Street Nc reported 0.22% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Point72 Asset Limited Partnership holds 1.28M shares or 0.36% of its portfolio.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Institutional Positions Chart